Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease ...Middle East

RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events Enrolment is now open for the study, with initial data readout expected in 2026...

Hence then, the article about resolution therapeutics announces first patient dosed in phase i ii emerald study of rtx001 for the treatment of end stage liver disease was published today ( Wednesday 03/09/2025 - 10:37 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease )

Also on site :

• One person in critical condition following two-vehicle collision on SR-126 at Boosey Road
• Kentucky congressman announces death of longtime staffer, campaign manager
• Man injured after jumping from upper floors of Grand Mosque in Makkah